Nicholas Cheung

• Advised life sciences investors, multinational pharmaceutical and healthcare companies, and biotech companies on cross border M&A, venture financing transactions, and other corporate transactions ranging from licensing, joint ventures, to various commercial initiatives, including supply and distribution arrangements.
• Advised Rubicon Founders in its US$165 million strategic growth investment in Caidya, a leading clinical research organization.
• Advised Medera, a clinical stage biopharma, in its equity financing, mergers and acquisitions, and licensing collaboration activities with global partners and targets.
• Advised Midea, a China-based global consumer electronics conglomerate, in its expansion into the medical device field, including its acquisition, licensing and investment in innovative products.
• Advised Corxel Pharmaceuticals, a clinical-stage biopharmaceutical company, on multiple divestitures, including its exclusive rights to develop and commercialize in Greater China region cardiovascular and ophthalmic drug candidates to Sanofi and Grand Pharmaceutical Group.
• Advised Zai Lab Limited, a dual listed company on Nasdaq and HKEX in its US$200 million secondary offering.
• Advised Erasca, a clinical-stage precision oncology company, in the exclusive license arrangement with Joyo Pharma for a pre-clinical RAS mutation targeting program with a potential oral tumor inhibitor in the worldwide territory (excluding mainland China, HK and Macau) for an aggregate consideration of up to US$189 million.
• Advised LianBio in its divestiture of its exclusive rights to develop and commercialize Mavacamten in certain territories to Bristol Myers Squibb for up to US$350 million.
• Advised Cohen & Company Capital Markets, acting as lead financial and capital markets advisor of ExcelFin Acquisition Corp. in a business combination agreement with China-based Baird Medical, representing an implied pro forma enterprise value of approximately US$370 million for the combined company.
• Advised Everest Medicines in its divestiture of its exclusive rights to develop and commercialize Trodelvy in certain territories to Gilead Sciences, Inc. for up to US$455 million.
• Advised J-Pharma, a Japanese bio-venture company, in an agreement with Georgetown University granting an exclusive worldwide license for the treatment of inflammatory diseases of the central nervous system
• Advised National Modern Energy in the sale of its stake in National Electric Vehicle Sweden to Evergrande Group for US$379.5 million.
• Advised a PRC conglomerate in the financial services, technology, consumer and healthcare sectors on its proposed acquisition of AXA Wealth Management (HK) Limited from AXA China for an aggregate consideration of HK$2.2 billion.*
• Advised venture capital investors and alternative asset managers on numerous Hong Kong IPO cornerstone investments and subsequent sell-down in companies in the TMT, healthcare, biotech and medical devices sectors.
• Advised companies listed on the Main Board of the Hong Kong Stock Exchange on securities compliance.

Notable transactions in which Nick has been involved prior to joining the firm include:

Equity Capital Markets*

• Advised 51 Credit Card, Inc. on its HK$1.0 billion initial public offering on the Main Board of the Hong Kong Stock Exchange
• Advised China Cinda Asset Management Co., Ltd. on its placing of new H shares to COSCO Shipping Financial Holdings Co., Limited for an aggregate consideration of approximately RMB5.49 billion
• Advised Postal Savings Bank of China Co., Ltd. on its HK$56.6 billion initial public offering on the Main Board of the Hong Kong Stock Exchange (awarded Global Finance Deal of the Year: Capital Markets (Equity) by American Lawyer, Equity Market Deal of the Year by Asian Legal Business, Deal of the Year by China Business Law Journal and Equity Deal of the Year by IFLR Asia)
• Advised China International Capital Corporation Limited on its HK$5,485.2 million initial public offering on the Main Board of the Hong Kong Stock Exchange (awarded Equity Deal of the Year by IFLR Asia)

Debt Capital Markets*

• Advised numerous debt offerings involving companies in the TMT, oil and gas and real estate sectors.
• Advised Tencent Holdings Limited in connection with its US$2.5 billion the Rule 144A and Regulation S notes offering
• Advised CNOOC Limited in connection with its US$3.8 billion SEC-Registered guaranteed notes offering
• Advised CNOOC Limited in connection with its US$4.0 billion SEC-Registered guaranteed notes offering (awarded Deal of the Year by China Business Law Journal)
• Advised Zhongsheng Group Holdings Limited on its repurchase of HK$2.35 billion convertible bonds due 2018 and issuance of HK$4.7 billion convertible bonds due 2023

*Includes transaction completed prior to joining Ropes & Gray